A Minnesota task force advising lawmakers on psychedelic medicine policy has recommended decriminalizing psilocybin mushrooms and establishing a state-regulated clinical program to treat mental health disorders.
Dried psilocybin mushroom.
The 23-member Psychedelic Medicine Task Force released its 191-page report on New Year’s Day. Composed of legislators, state agency heads, tribal representatives, veterans, and healthcare professionals, the group approved the recommendations with a two-thirds majority. The group also called for funding research into the health benefits of psilocybin, MDMA, and LSD.
The report prioritizes psilocybin decriminalization and clinical use, citing its natural origin compared to synthetic substances like MDMA and LSD.
The report highlights the therapeutic potential of psilocybin, MDMA, and LSD, all of which have received FDA “breakthrough therapy” designations. Evidence suggests psilocybin may help treat depression, anxiety, substance use disorders, and eating disorders. MDMA shows promise as a treatment for PTSD, while LSD may address anxiety disorders.
For the full report, click here.
